J hormone-blocking tablet slows prostate cancer spread

<p>CHICAGO (Reuters) A hearing of Johnson Johnsons Zytiga in certain prostate cancer patients showed that it doubled a volume of time they lived yet a illness removing worse, potentially charity new wish for patients who see their cancer return.
The trial, involving 1,088 patients who had stopped responding to normal hormonal drugs yet had not been treated with chemotherapy, found that Zytiga slowed a widespread of a illness by 58 percent.
Zytiga is one of several new prostate cancer treatments that might significantly lengthen a life of patients by zeroing in some-more closely on certain mechanisms that assistance tumors proliferate. New information on a drugs are being presented during a American Society of Clinical Oncology (ASCO) annual assembly in Chicago.
The drugs strong formula in earlier-stage cancer it is already authorized for group with prostate cancer who formerly perceived chemotherapy have implications for companies lik...